


*Ap 1652*  
ocket No.: PF-0148-2 DIV

RECEIVED

DEC 14 1999

TECH CENTER 1600/2900



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box Non-Fee Amendment, Assistant Commissioner for Patents, Washington, D.C. 20231 on December 10, 1999  
By: *[Signature]*  
Printed: Nancy L. Glynn

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hawkins et al.

Title: HUMAN PYROPHOSPHATASE

Serial No.: 09/415,540

Filing Date: October 8, 1999

Examiner: Slobodyansky, E.

Group Art 1652

Assistant Commissioner for Patents  
Washington, D.C. 20231

AMENDMENT TRANSMITTAL FEE SHEET

Sir:

Transmitted herewith are the following for the above-identified application:

1. Return Receipt Postcard;
  2. Response to Restriction Requirement (4 pp., in duplicate);
- The fee has been calculated as shown below.

Claims	Claims After Amendment	=	Claims Previously Paid For	=	Present Extra	Other Than Small Entity Rate	Additional Fee(s)
Total Claims	6	-	20	=	0	\$18	\$0
Indep. Claims	2	-	3	=	0	\$78	\$0
First Presentation of Multiple Dependent Claim						+\$260	\$0
TOTAL						\$ 0	

No additional fee is required.

Please charge Incyte Pharmaceuticals, Inc. Deposit Account No. 09-0108 the amount of \$ \_\_\_\_\_

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17, or credit overpayment to Incyte Pharmaceuticals, Inc. Deposit Account No. 09-0108. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

INCYTE PHARMACEUTICALS, INC.

*Diana Hamlet-Cox*  
Diana Hamlet-Cox, Ph.D.  
Reg. No. 33,302

Date: 10 December 1999  
3174 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 845-4639 Fax: (650) 849-8886

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box Non-Fee Amendment, Assistant Commissioner for Patents, Washington, D.C. 20231 on December 10, 1999.  
 By: *[Signature]*  
 Printed: Nancy L. Glynn



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hawkins et al.

Title: HUMAN PYROPHOSPHATASE

Serial No.: 09/415,540

Filing Date: October 8, 1999

Examiner: E. Slobodyansky

Group Art Unit: 1652

Box Non-Fee Amendment  
 Assistant Commissioner for Patents  
 Washington, D.C. 20231

**RESPONSE TO RESTRICTION REQUIREMENT UNDER 35 U.S.C. 121**

Sir:

This is in response to the Restriction Requirement mailed November 12, 1999 in the above-referenced application.

Please amend the application for the above-referenced as follows:

**IN THE CLAIMS:**

**Please cancel claim 17, without prejudice or disclaimer.**

**Please amend the claims as follows:**

1. (Once Amended.) A substantially purified [human pyrophosphatase (HPYP)] polypeptide comprising [the] an amino acid sequence selected from the group consisting of

- a) an amino acid sequence of SEQ ID NO:1 [or fragments thereof],
- b) a naturally-occurring amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO:1,